November 22, 2012 / 9:19 AM / 5 years ago

MARKET EYE-Pharma stocks fall on speculation over pricing policy

* Shares in Indian drugmakers fall on speculation the
government's final decision on the pricing policy for the sector
might be more disruptive than expected.
* Local media reports suggest a panel of ministers has agreed to
settle on a market-based pricing mechanism, as expected, but
capping drug prices at a simple average price of brands as
opposed to the initial proposal of using a weighted average. link.reuters.com/jur24t
* The proposal, if finalised, would be "incrementally negative"
for the sector, but the impact would vary from company to
company, Nomura says in a note on Thursday.
* The new proposal is likely to be more negative for Dr Reddy's
, Glenmark and Cadila Healthcare,
Nomura says. 
* Cipla falls 0.1 percent, while Ranbaxy Laboratories
 is down 0.9 percent. 
* Dr Reddy's Laboratories is flat, Glenmark Pharmaceuticals is
up 3.9 percent and Cadila gains 2.2 percent.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net/kaustubh.kulkarni@thoms
onreuters.com /; kaustubh.kulkarni.reuters.com@reuters.net)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below